Editor's Note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EDT on CNBC.

Should I sell La Jolla Pharma (LJPC) - Get Report?-- Bernadette from Forest Hills, N.Y.

James J. Cramer

: I say that there is plenty of room for speculation in one's investment portfolio. That said, there are an extraordinary amount of potential land mines in the biotech sector.

As a general rule, I believe viewers should avoid speculating in stocks trading below $1 -- unless they've first conducted a lot of homework on the company.

What are your thoughts on Pfizer (PFE) - Get Report?-- Don from Illinois

Image placeholder title

Cramer

: I am largely bearish on the large-cap drug stocks at this time, as patent expirations pile up and there are very few potential blockbusters in the pipeline.

Outside of

Bristol-Myers

(BMY) - Get Report

, which has been given little credit for its recovering drug sales and attractive 4.5% dividend, I believe there is little money to be made in this group for the long term.

Interested in more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

. It's a series of articles from Cramer on how to become a better investor. The following table lists some of the rules that Cramer dissects.